Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 8/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | KMT5A | Q9NQR1 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | CDC25C | P30307 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13470064 | 0.72 | CDK4 (0.45) | CDK4PTGS2PTGS1KMT5AMEN1 | |
| SCHEMBL13470368 | 0.72 | CDK4 (0.45) | CDK4PTGS2PTGS1KMT5AMEN1 | |
| SCHEMBL31060254 | 0.65 | CDK4 (0.44) | CDK4PTGS2PTGS1KMT5AMEN1 | |
| SCHEMBL7816362 | 0.64 | IDO1 (0.55) | CDK4PTGS2PTGS1KMT5AMEN1 | |
| SCHEMBL16885422 | 0.63 | CDK4 (0.46) | CDK4PTGS2PTGS1MEN1THRB | |
| SCHEMBL15436988 | 0.62 | ALOX5 (0.33) | CDK4PTGS2PTGS1KMT5AMEN1 | |
| SCHEMBL16284914 | 0.61 | ALOX5 (0.36) | CDK4PTGS2PTGS1KMT5AMEN1 | |
| SCHEMBL14217298 | 0.57 | TSHR (0.41) | TDP1 | |
| SCHEMBL13434368 | 0.56 | TSHR (0.33) | — | |
| SCHEMBL12335757 | 0.56 | ALOX5 (0.61) | CDK4ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1819701-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058630-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006058630-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | CDK4 736/4885PTGS2 821/4885PTGS1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.